The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HROW | -4.83% | +536.35% | +44.73% | +372% |
| S&P | +13.19% | +87.83% | +13.42% | +355% |
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
The company increased guidance, acquired a company, and had a stock sale.
The pharmaceutical company announced first-quarter earnings Thursday afternoon.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $71.64M | 45.4% |
| Gross Profit | $53.93M | 44.8% |
| Gross Margin | 75.28% | -0.3% |
| Market Cap | $1.78B | 11.8% |
| Market Cap / Employee | $4.67M | 0.0% |
| Employees | 382 | 21.3% |
| Net Income | $1.02M | 124.2% |
| EBITDA | $19.65M | 320.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $74.29M | 2.3% |
| Accounts Receivable | $77.60M | 44.4% |
| Inventory | 12.8 | 26.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $251.01M | 28.4% |
| Short Term Debt | $0.86M | 69.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1.40% | 9.1% |
| Return On Invested Capital | -10.58% | -1.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $16.38M | 597.8% |
| Operating Free Cash Flow | $16.59M | 462.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 20.74 | 13.60 | 19.29 | 35.62 | 29.71% |
| Price to Sales | 6.02 | 4.48 | 5.21 | 7.49 | -21.07% |
| Price to Tangible Book Value | -9.05 | -8.07 | -8.62 | -13.73 | -16.38% |
| Price to Free Cash Flow TTM | 528.19 | 2263.62 | 466.80 | 113.02 | 53.41% |
| Enterprise Value to EBITDA | 76.97 | -176.46 | 83.65 | 104.36 | -71.82% |
| Free Cash Flow Yield | 0.2% | 0.0% | 0.2% | 0.9% | -34.82% |
| Return on Equity | -25.0% | -37.2% | -19.0% | -9.5% | -80.97% |
| Total Debt | $228.83M | $230.01M | $231.25M | $251.87M | 28.46% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
